Viread now also approved to treat hepatitis B

August 13, 2008

The drug is administered as a once-daily tablet.

The anti-HIV drug Viread (tenofovir disoproxil fumarate, Gilead Sciences) has gained a new indication: to treat chronic hepatitis B in adults. Administered as a once-daily tablet, the drug works by blocking an enzyme required by the hepatitis B virus to replicate in liver cells. Hepatitis B is most prevalent among Asian Americans in this country.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, clickhere.